An inhibitor of mmu-miR-7212-5p enhances Hmox1 expression and mitigates ferroptosis by diminishing Acsl4 expression, suggesting that mmu-miR-7212-5p inhibitors may represent a promising clinical therapeutic target for sepsis-related AKI. Here, ACSL4 is linked to acute kidney injury.